Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes – The Focus of Gene Therapy – PRNewswire

DUBLIN, Sept. 20, 2019 /PRNewswire/ -- The "Global & US Gene Therapy Market Forecast to 2020" report has been added to ResearchAndMarkets.com's offering.

Gene therapy is one of the most widely researched fields in the healthcare industry. The high potential of gene therapy to cure various chronic diseases makes it a popular research area. Various researches are being performed across the globe to explore the potential of gene therapy for the treatment of incurable diseases, such as diabetes, cancer, and HIV amongst others.

According to this new research report "Global & US Gene Therapy Market Forecast to 2020, most of the gene therapy researches are being focused on finding the treatment for cancer, followed by genetic diseases and neurological disorders, respectively. In this context, the gene therapy application chapter of the report provides a comprehensive overview of various diseases in which the gene therapy is used, along with the current and future market size of gene therapy for particular disease and its geographical break up. Primarily, the gene therapy market is dominated by oncology applications, with several companies and academic institutions focusing on novel and difficult to treat' cancers. Other therapeutic areas seeking developments in gene therapy include monogenic diseases, cardiovascular diseases, infectious diseases, inherited blindness and neurological diseases. Furthermore, the chapter also provides details regarding the various aspects of the clinical trials in the different gene therapy application by phases, vector types, etc.

The major part of the revenue of gene therapy market is generated from research phase. Most of the gene therapy products are in research phases, only few products have been commercialized till date. The report also provides the sales of major marketed gene therapy products, and the list of the products in clinical/pre-clinical research along with their clinical phases.

The companies operating in the gene therapy market are also receiving various funding, grants, and investment from government bodies and venture capitalist firms which are aiding them to develop new products. The study highlights the applications for which the investments have been received.

North America continues to have the maximum number of clinical trials in the gene therapy segment. This is a major reason for the dominant position of North America in the gene therapy market. Based on the geography, the market is divided into four regions, namely, North America, Europe, Asia, and Rest of the World. The report provides the market for each of the geography, along with its forecast till 2020.

Gene silencing, advanced therapies combining gene therapy and stem cell technology, immunodeficiency syndromes, growing interest of venture capital firms, etc. will propel the industry's growth. An analysis has also been done of a few factors limiting the growth of the industry. The report also provides insights regarding the strategies adopted by the players from 2013 to 2015 for enhancing their market share. Finally, with a view to understand the competitive landscape, the profiles of key market players have been included in the report to present a complete picture of the global gene therapy market.

Key Topics Covered:

1. Analyst View

2. Research Methodology

3. Gene Therapy - An Introduction3.1 Classification of Gene Therapy Techniques3.2 Physical Methods of Gene Transfer3.2.1 Electroporation3.2.2 Hydrodynamic3.2.3 Microinjection3.2.4 Particle Bombardment3.2.5 Ultrasound-Mediated Transfection3.3 Vectors for Gene Therapy3.3.1 Viral Vectors3.3.1.1 Adenoviral Vectors3.3.1.2 Adeno-associated Virus Vectors3.3.1.3 Retroviral Vectors3.3.1.4 Lentiviral Vectors3.3.2 Non Viral Vectors3.3.2.1 Naked DNA/Plasmid Vectors3.3.2.2 Oligonucleotides3.3.2.3 Liposomes, Lipoplexes and Polyplexes3.3.2.4 Gene-Activated Matrix

4. Industry Overview4.1 Market Drivers4.1.1 Failure of Conventional Therapies to Treat Cancers4.1.2 Rising Focus to Accelerate Commercialization of Gene Therapy in Developed Nations 4.1.3 Rising Incidence of Chronic and Life-Threatening Diseases4.1.4 Growing Interest of Venture Capital Firms4.2 Market Restraints4.2.1 Stringent Regulatory Laws & Safety Concerns 4.2.2 Challenges in Commercialization of Gene Therapy4.2.3 High Cost of the Gene Therapy Drugs4.2.4 Pitfalls in Current Technique4.2.5 Production & Manufacturing: A Unique Challenge for Gene Therapies 4.3 Market Opportunities4.3.1 Approval of Gene Therapy Drug in Europe4.3.2 Gene Therapy for Hemophilia B Offers Significant Opportunity 4.4 Industry Trends4.4.1 Gene Silencing: Gaining Momentum4.4.2 Advanced Therapies: Combining Gene Therapy and Stem Cell Technology4.4.3 Immunodeficiency Syndromes: The Focus of Gene Therapy4.4.4 Nanotechnology: Empowering Gene Therapy4.4.5 Gene Therapy: A New Hope to Treat Blindness4.4.6 Gene Therapy: Potential Cure for Cancer4.5 Winning Imperatives4.5.1 Investment in R&D Activities

5. Clinical Trial Assessment & Pipeline Analysis5.1 Clinical Trials5.1.1 By Geography5.1.2 By Indication5.1.3 By Gene Type5.1.4 By Vector5.1.5 By Clinical Trial Phase5.2 Pipeline Analysis

6. Gene Therapy Market - Regulatory Landscape & Reimbursement Scenario6.1 Regulatory Landscape6.1.1 US6.1.2 Canada6.1.3 Europe 6.1.4 Japan6.1.5 China6.1.6 India6.1.7 Australia6.2 Reimbursement Scenario in Global Market

7. Marketed Gene Therapies7.1 Neovasculgen7.2 Glybera7.3 Gendicine, Rexin-G, Oncorine7.3.1 Gendicine7.3.2 Rexin G 7.3.3 Oncorine

8. Gene Therapy Market8.1 Global8.2 US

9. Gene Therapy Market by Application9.1 Oncology9.1.1 Clinical Trials 9.1.2 Prevalence9.1.3 Market Outlook9.2 Cardiovascular Diseases9.3 Infectious Diseases9.4 Neurological Diseases9.5 Genetic Diseases9.6 Others

10. Gene Therapy Market Size by Geography10.1 North America10.2 Europe10.3 Asia10.4 Rest of the World (RoW)

11. Competitive Landscape11.1 Strategies Adopted by Various Players11.1.1 Strategic Collaborations11.1.2 Acquisitions 11.1.3 Funding & Investments11.2 Companies Progress in Gene Therapy In 2015

12. Key Players Analysis (Business Description, Clinical Pipeline, Recent Developments, Strengths & Weaknesses)12.1 Spark Therapeutics, LLC12.2 ViroMed Co. Ltd. dba VM BioPharma12.3 Advantagene Inc.12.4 Bluebird Bio12.5 Sanofi12.6 Vical Inc.12.7 Oxford BioMedica Plc12.8 Genethon12.9 uniQure N.V.12.10 Human Stem Cells Institute12.11 Shanghai Sunway Biotech Co. Ltd.12.12 Sibiono GeneTech Co. Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/g01of6

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470 For U.S./CAN Toll Free Call +1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716

SOURCE Research and Markets

http://www.researchandmarkets.com

Continue reading here:
Global & US Gene Therapy Market 2019-2020: Immunodeficiency Syndromes - The Focus of Gene Therapy - PRNewswire

Related Post